WO2023148525 - 2'-FUCOSYLLACTOSE AND LACTO-N-NEOTETRAOSE FOR PREVENTING AND TREATING OVERWEIGHT
National phase entry:
Publication Number
WO/2023/148525
Publication Date
10.08.2023
International Application No.
PCT/IB2022/050979
International Filing Date
04.02.2022
Title **
[English]
2'-FUCOSYLLACTOSE AND LACTO-N-NEOTETRAOSE FOR PREVENTING AND TREATING OVERWEIGHT
[French]
2'-FUCOSYLLACTOSE ET LACTO-N-NÉOTÉTRAOSE POUR PRÉVENIR ET TRAITER LE SURPOIDS
Applicants **
HEALTH AND HAPPINESS (H&H) HONG KONG LTD
Suites4007-09/F
One Island East Taikoo Olace
18 Westlands Rad Quarry Bay
Hong Kong, Hong Kong, CN
Inventors
JONATHAN, Lane
National Food Innovation Hub
Teagasc Moorepark
Fermoy
CORK, P61K02, IE
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
CNIPA
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 944 | |
| EPO | Filing, Examination | 6431 | |
| Japan | Filing | 594 | |
| South Korea | Filing | 482 | |
| USA | Filing, Examination | 2710 |
Total: 11161 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
It relates to the use of 2 '-fucosyllactose and Lacto-N-neotetraose for treating and/or reducing weight in a subject in need thereof. It also relates to pharmaceutical and food compositions containing these compounds.[French]
L'invention concerne l'utilisation de 2'-fucosyllactose et de lacto-N-néotétraose pour traiter et/ou réduire le poids d'un sujet le nécessitant. L'invention concerne également des compositions pharmaceutiques et alimentaires contenant ces composés.